A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Parallel-Cohort, Single-Dose Escalation, And Multiple-Dose Titration Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2011
At a glance
- Drugs Latrepirdine (Primary)
- Indications Alzheimer's disease; Huntington's disease
- Focus Pharmacokinetics
- Sponsors Pfizer
- 16 Jun 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Feb 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 13 Feb 2009 Additional location identified as reported by ClinicalTrials.gov, last updated 13 Feb 2009.